It is a prime concern of Evotec that all relevant target groups receive the same information at the same time. This implies communicating in both English and German.

Please find below the most recent corporate news, ad hoc releases and other announcements of our Company.

 

2016

Henning Steinhagen appointed as Executive Vice President Drug Discovery and Development and Site-Head Verona
Jim Regan, 14 June 2016

We are pleased to announce the appointment of Henning Steinhagen, PhD, as Executive Vice President Drug Discovery and Development, and Site-Head Verona, completing Aptuit’s executive leadership team.

Iain Rusling, Appointed VP of Quality Management and EHS
Jim Regan, 25 April 2016

We are pleased to announce the appointment of Iain Rusling as Vice President of Quality Management and EHS. Iain joins us directly from Sandoz, where he was Head of Third Party QA, Europe/META. In this role he led all quality aspects for over 350 third party contract manufacturers in Western Europe in a cGMP regulatory environment. Prior to...

Vince Russell, Appointed Respiratory Discovery Director
Jim Regan, 29 February 2016

We are very happy to announce the appointment of Vince Russell as Respiratory Discovery Director at Aptuit. Vince joins us with more than 26 years of experience in pharma, biotech and CRO drug discovery in the respiratory disease area. Most recently Vince spent six years as part of Argenta's senior management team. In this time he was...

Mario Maio, Appointed Global Head of CMC
Jim Regan, 17 February 2016

We are very happy to announce the appointment of Mario Maio as Global Head of CMC at Aptuit. Mario joins us after many years of R&D, and management & strategic experience in large pharmaceutical companies such as Roche, Merck, and Janssen. His career to date has seen him spend time in Italy, Germany and Switzerland.

 

Other announcements

Merger

The following annoucement has been published in the German Federal Gazette in accordance with the German Conversion Act (Umwandlungsgesetz) in 2013. Pursuant to the German Conversion Act, certain transaction intended by Evotec AG, e.g. up-stream mergers, have to be announced in the Federal Gazette (Bundesanzeiger).

Contact us

Gabriele Hansen

VP, Corporate Communications & Investor Relations

T +49 40 560 81 255 F +49 40 560 81 333 vCard

Katja Werner

Investor Relations Associate

T +49 40 560 81 210 F +49 40 560 81 333 vCard